Investigational drug · Phase 2
Liso-cel
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Lymphoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
33
Any phase or sponsor naming "Liso-cel"
First trial start
2025
Nov 6, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Liso-cel", any sponsor or status.
- Phase 217
Conditions studied
As listed on its trial records.
- Lymphoma
Approved drugs for the same conditions: Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Liso-cel" as an intervention, largest first.
- A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyPivotal-lookingRecruiting
Lyell Immunopharma, Inc.Industry
NCT07188558 · 400 participants (planned) · Start Jan 12, 2026 · Primary completion Dec 2029
Drug: rondecabtagene autoleucel; axicabtagene ciloleucel and 1 more · For: Large B-cell Lymphoma; Lymphoma, B-Cell; Relapsed Non-Hodgkin Lymphoma and 6 more
Sites: Gilbert, Arizona; Scottsdale, Arizona; Little Rock, Arkansas · 44 sites in all
- Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaPivotal-lookingRecruiting
SWOG Cancer Research NetworkResearch network
NCT05633615 · 396 participants (planned) · Start Jun 12, 2023 · Primary completion Jun 30, 2030
Drug: Axicabtagene Ciloleucel; Cyclophosphamide and 5 more · For: Diffuse Large B-Cell Lymphoma; Grade 3b Follicular Lymphoma; Primary Mediastinal (Thymic) Large B-Cell Lymphoma and 4 more
Sites: Tucson, Arizona; Fayetteville, Arkansas; Little Rock, Arkansas · 95 sites in all
Juno Therapeutics, a Subsidiary of CelgeneBristol Myers Squibb (BMY)
NCT02631044 · 387 participants · Start Jan 6, 2016 · Primary completion May 16, 2024
Drug: JCAR017 (lisocabtagene maraleucel) single-dose schedule; JCAR017 (lisocabtagene maraleucel) 2-dose schedule · For: Non-Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma; Follicular Lymphoma and 2 more
Sites: Birmingham, Alabama; Duarte, California; San Francisco, California · 14 sites in all
- Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)Active, not recruiting
Juno Therapeutics, a Subsidiary of CelgeneBristol Myers Squibb (BMY)
NCT03331198 · 320 participants (planned) · Start Nov 27, 2017 · Primary completion Nov 26, 2027
Drug: JCAR017 (lisocabtagene maraleucel); JCAR017 (lisocabtagene maraleucel) + ibrutinib and 1 more · For: Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Small Lymphocytic
Sites: Birmingham, Alabama; Gilbert, Arizona; Duarte, California · 84 sites in all
Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyBristol Myers Squibb (BMY)
NCT06788639 · 300 participants (planned) · Start Feb 4, 2025 · Primary completion Jun 30, 2044
Drug: Lisocabtagene maraleucel · For: Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)
Sites: Milwaukee, Wisconsin
Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyBristol Myers Squibb (BMY)
NCT06794268 · 300 participants (planned) · Start Feb 4, 2025 · Primary completion Aug 31, 2044
Drug: Lisocabtagene maraleucel · For: Follicular Lymphoma
Sites: Milwaukee, Wisconsin
- Liso-Cel in Relapsed/Refractory Marginal Zone LymphomaActive, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07777120 · 300 participants (planned) · Start Mar 24, 2026 · Primary completion Mar 31, 2048
Drug: lisocabtagene maraleucel · For: Marginal Zone Lymphoma
Sites: Milwaukee, Wisconsin
Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyBristol Myers Squibb (BMY)
NCT06788652 · 300 participants (planned) · Start Feb 4, 2025 · Primary completion Sep 30, 2044
Drug: Lisocabtagene maraleucel · For: Mantle Cell Lymphoma (MCL)
Sites: Milwaukee, Wisconsin
- A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin LymphomasPivotal-lookingCompleted
CelgeneBristol Myers Squibb (BMY)
NCT03575351 · 184 participants · Start Oct 23, 2018 · Primary completion Oct 23, 2023
Drug: Standard of Care · For: Lymphoma, Non-Hodgkin
Sites: Scottsdale, Arizona; San Francisco, California; Aurora, Colorado · 54 sites in all
CelgeneBristol Myers Squibb (BMY)
NCT03484702 · 113 participants · Start Jun 5, 2018 · Primary completion Dec 15, 2023
Drug: JCAR017 · For: Lymphoma, Non-Hodgkin
Sites: Vienna, Austria; Ghent, Belgium; Helsinki, Finland · 20 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- InflaMix Predicts Severe CRS, ICU Admission, and Progression-Free Survival After CAR-T Therapy in LBCL.
Galli E, Mannina D, Corrente A, et al. · Eur J Haematol 2026
- Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004.
Wierda WG, Dorritie K, Gauthier J, et al. · Blood 2026
- Care pathway of patients with second-line large B-cell lymphoma treated with CAR T-cell therapies in France.
Colrat F, Despas F, Branchoux S, et al. · Leuk Lymphoma 2026
- Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel as Second-Line Treatment for Large B Cell Lymphoma in the United States.
Deger KA, Liu FF, Klijn SL, et al. · Adv Ther 2026
- Efficacy and safety of lisocabtagene maraleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: 31-month follow-up of the phase 2 TRANSCEND FL study.
Makita S, Goto H, Izutsu K, et al. · Int J Clin Oncol 2026
- Safety Profile of Chimeric Antigen Receptor T-cell Therapies in Diffuse Large B-cell Lymphoma: An Analysis of Real-World Adverse Event Reporting From the FDA Adverse Event Reporting System.
Elsallab M, Lunning M, Ellithi M, et al. · Mayo Clin Proc Innov Qual Outcomes 2026
Also in development for Lymphoma
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- OSE2101Phase 32 trials
OSE Immunotherapeutics · Patients With Non-Small Cell Lung Cancer, Solid Advanced Tumor, Lymphoma
- GecacitinibPhase 24 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Lymphoma, Non-small Cell Lung Cancer, Advanced Solid Tumor
- AZD3470Phase 22 trials
AstraZeneca · Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
- COH04S1GEO-CM04S1, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1Phase 22 trials
GeoVax, Inc. · COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia
- ASTX660Phase 21 trial
Taiho Oncology, Inc. · Solid Tumors, Lymphoma
- BT02Phase 21 trial
Biotroy Therapeutics · Relapsed or Refractory Hematologic Malignancies, Leukemia, Lymphoma
- CTS3497Phase 21 trial
CytosinLab Therapeutics Co., Ltd. · Solid Tumor, Lymphoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.